What is Sucraid®?

Sucraid® (sacrosidase) Oral Solution is the only FDA-approved enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

What is CSID?

CSID, more commonly known as Sucrose Intolerance or carbohydrate malabsorption, is a rare disorder that diminishes one’s ability to digest sucrose and dietary starches into absorbable monosaccharides, due to absent or low activity of two digestive enzymes, sucrase and maltase.

The symptoms of CSID include postprandial diarrhea, excess gas, bloating, and abdominal pain. Infants with CSID typically experience caustic diaper rash and failure to thrive.

The clinical symptoms of CSID are shared by several common GI conditions, making it difficult at times to determine the cause and appropriate treatment.

Sucraid® Treats CSID

When the diagnosis is CISD, the appropriate pharmaceutical treatment is Sucraid®. Go to www.sucraid.com/hcp for more information on how to treat CSID with Sucraid®.

Please see Sucraid® full Prescribing Information at Sucraid® PI 2023.

Sucraid® (sacrosidase) Oral Solution

Indication

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

• Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
• Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
• Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
• Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
• Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
• The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
• DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
• Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.